Crispenes F and G, cis-Clerodane Furanoditerpenoids from Tinospora crispa, Inhibit STAT3 Dimerization by Noman, Md Abdullah Al et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1021/acs.jnatprod.7b00377
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Noman, M. A. A., Hossain, T., Ahsan, M., Jamshidi, S., Hasan, C. M., & Rahman, K. M. (2018). Crispenes F and
G, cis-Clerodane Furanoditerpenoids from Tinospora crispa, Inhibit STAT3 Dimerization. Journal of Natural
Products, 81(2), 236-242. https://doi.org/10.1021/acs.jnatprod.7b00377
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Crispenes F and G, cis-Clerodane Furanoditerpenoids from Tinospora crispa, Inhibit 
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ABSTRACT 
Two new cis-clerodane-type furanoditerpenes, crispenes F and G (1 and 2), together with 
seven known compounds, were isolated from the stems of Tinospora crispa. Crispenes F 
and G (1 and 2) inhibited STAT3 dimerization in a cell-free fluorescent polarization (FP) 
assay, and were found to have significant cytotoxicity against a STAT3-dependent 
MDA-MB 231 breast cancer cell line, while being inactive in a STAT3-null A4 cell line. 
These two compounds share structural similarities with a previously reported STAT3 
inhibitor, crispene E, isolated from the same plant.  Molecular docking studies suggested 
that the molecules inhibit STAT3 by interacting with its SH2 domain.  
 
 
  
 Oncogenic transcription factors are an increasingly important target for anticancer 
therapies, as their inhibition could allow for the “reprogramming” of tumor cells, leading to 
apoptosis or differentiation from the malignant phenotype.1,2 Signal Transducer and Activator 
of Transcription Protein 3 (STAT3) has emerged as a promising molecular target for 
chemotherapy.3 In vivo studies have demonstrated that STAT3 is constitutively active in a 
variety of malignancies, ranging from breast, prostate, and head and neck tumors to multiple 
myelomas and hematological cancers.4 Cancer cells are often dependent upon the activation 
of STAT3, but non-cancerous cells are fairly tolerant of the loss of STAT3 function, likely 
reflecting redundancies in normal signal transduction.5 This suggests a high therapeutic 
potential for STAT3 inhibitors. Furthermore, targeting STAT3 could potentially eliminate 
chemoresistance, as a number of signaling pathways converge on STATs and the inhibition 
of these proteins may forestall resistance.6 Several growth factors or cytokines stimulate the 
STAT3 signaling pathway, which leads to receptor dimerization and activation. 
Phosphorylation of the tail of the receptor creates a docking site for the recruitment of an un-
phosphorylated STAT3 (uSTAT3), which becomes phosphorylated at the Tyr705 position 
(near the C-terminus) by JAK kinases. The phosphorylation of the STAT3 protein leads to 
the formation of a homodimer through the reciprocal binding of the SH2 domain of one 
monomer to the pTyr-containing PYLKTK sequence of another. This dimeric pSTAT3 acts 
as a transcription factor by translocating to the nucleus, where it binds to its DNA consensus 
sequence, thus regulating the transcription of numerous genes critical for the survival and 
proliferation of cancer cells.7,8 A number of different approaches have been taken to identify 
novel small molecules as STAT3:STAT3 dimerization inhibitors, including the development 
of peptides or  peptidomimetics that bind to the STAT3 SH2 domain,9 and small molecules, 
derived from STAT3 structural information and in silico design, which interact with the key 
residues within the STAT3 SH2 domain.10-12  A number of plant-derived molecules have also 
shown potent inhibition of the STAT3 signalling pathway and STAT3 dimerization.13-16 
 
 Historically, plants have represented an important pool for the identification of novel drug 
leads. There is increasing interest in searching for natural products with drug-like properties 
as potential preclinical candidates.17 A fluorescent polarization assay has been used to study 
plant isolates with drug-like properties, including the previously reported crispene E, a cis-
clerodane diterpene, as a STAT3 dimerization inhibitor.16 As part of ongoing work to identify 
bio active plant metabolites from Bangladeshi medicinal plants,16, 18-20 crispene F (1) and 
crispene G (2), two structurally related furanoid diterpenes with STAT3-inhibitory activity, 
were identified from Tinospora crispa Diels (Menispermaceae), a woody climber native to 
Malaysia, Indochina, the Indian subcontinent, and mainland China.21 In traditional medicine, 
this species is used for the treatment of hypertension, diabetes mellitus, malaria, diarrhea, and 
as a vermifuge.22, 23  All three of these diterpenes (1, 2 and crispene E) with a STAT3 
dimerization inhibition property are drug-like, according to Lipinski’s rule of five,24  and  the 
core scaffold is amenable for further medicinal-chemistry optimization. This may provide 
opportunities to enhance the STAT3 inhibitory activity and cytotoxicity of the scaffold in 
STAT3-dependent tumors.  
 
RESULTS AND DISCUSSION 
 A methanol extract of the stem of Tinospora crispa led to the isolation of four clerodane-
type furanoditerpene lactones (1-4), an alkaloid (5) and three terpenoids (6-8), and a sterol 
(9). Among the isolated diterpenes, compounds 1 and 2 are new, with a carboxylic acid group 
at position C-8 as found previously only in crispene C.25 The known compounds were 
identified as crispene D (3),25 columbin (4),26  N-trans-feruloyltyramine (5),27 
cycloeucalenone (6),28  β-amyrin (7),29  lupeol (8), and β-sitosterol (9), by comparison of 
their spectroscopic data with those reported in the literature and by co-TLC with authentic 
samples. 
 
  
Table 1.  NMR Spectroscopic Data (J in Hz) for Crispenes F (1)a and G (2)b 
crispene F (1)  crispene G (2) 
position δC δH (Jin Hz) HMBC  δC δH (Jin Hz) 
1  28.6 2.01, ddd (14.6, 11.5, 6.7),          
2.29, dd (14.6, 7.0) 
2, 3, 5, 9, 10 74.9 5.19, br s 
2  64.7 4.55, dd (11.5, 7.0) 3, 4 129.5 6.49, dd (7.2, 4.4) 
3  139.7 6.71, s 1, 5, 18 136.8 6.40, d (7.2) 
4  137.0   80.3  
5  37.7   36.9  
6  138.2 6.56, s 5, 8, 10 26.6 1.96, d (16) 2.48, dd 
(16, 8.0) 
7  121.2 6.56 s 5, 8, 17 141.4 7.14, br d (8.0) 
8  78.4   137.7  
9  39.5   42.3  
10  45.6 2.52, d (6.1) 1, 5, 9, 19, 20 44.7 1.72, br s 
11  39.8 1.96, dd (13.5, 8.5) 2.25, dd 
(13.5, 8.5) 
8, 9, 12, 13, 20 55.3 2.07, br d (5.6) 
12  71.1 5.59, br t (8.5) 13, 14 69.9 4.93, br t (6.4) 
13  126.0   123.3  
14  108.6 6.40, br s 15, 16 108.6 6.45, br s 
15  144.3 7.43, br s 13, 16 143.9 7.43, br s 
16  139.6 7.46, br s 13, 14, 15 140.1 7.50, br s 
17  167.4   166.6  
18  166.9   175.3  
19  30.6 1.55, 3H s 5, 6, 10 25.5 1.13, 3H s 
20  23.4 0.95, 3H s 8, 9, 10, 11 30.6 1.20, 3H s 
-OCH3 52.1 3.73, 3H s 18   
OCOCH3 168.8     
OCOCH3 21.3 2.11, 3H s OC=O   
 
aIn CDCl3; 1H NMR in 600 MHz;  13C NMR in 150 MHz;  b In CDCl3; 1H NMR in 400 MHz; 13C NMR in 100 
MHz. 
 
 
  
  Compound 1, isolated as colorless needles, gave the molecular formula C23H28O9, as 
determined by HRESIMS measured in the negative-ion mode (m/z 447.1667 [M-H]- ). The 
1H NMR spectrum (Table 1) displayed resonances for three olefinic protons at δH 6.40, 7.43 
and 7.46 (1H, br s each), assignable to protons of a furan ring as commonly observed in 
clerodane-type furanoid diterpenes isolated from Tinospora species.30 Two characteristic 
angular methyl groups were observed at δH 1.55 (3H, s, Me-19) and δH 0.95 (3H, s, Me-20). 
A singlet at δ 6.71 (1H br s) was assigned to the C-3 proton of the trisubstituted double bond. 
This was confirmed by HMBC correlations from H-3 to C-1 and C-5 (Table 1, Figure 1). A 
broad olefinic proton signal at δ 6.56, which integrated for two protons (H-6 and H-7), 
showed direct correlations to C-6 and C-7 in the HSQC experiment and 2/3J correlations to C-
5 and C-8 in the HMBC spectrum. The 1H and 13C NMR spectra further revealed the 
presence of two oxymethine protons (δH 4.55, δC 64.7, H-2; δH 5.59, δC 71.1, H-12), an 
acetoxy methyl (δH 2.11, δC 21.3 and δC 168.8), and an ester methyl (δH 3.73, δC 52.1 and δC 
166.9).  In addition, the 13C NMR spectrum revealed the presence of a carboxylic acid 
carbonyl group at δC 167.4, which was assigned as C-17. The NOESY spectrum showed 
correlations between H-2/H-20 and H-10 /H-19, suggesting OH-2 and H-10 and Me-19 as α 
and H-2 and Me-20 as β. From the spectroscopic data obtained, 1 was characterized as 
(2R,5R,9S,10S)-15,16 epoxy-2,8α-dihydroxy-12-acetoxycleroda-3,6,13(16),14-tetraen-18-
methoxycarbonyl-17-oic acid, a new diterpene, which was given the trivial name crispene F. 
 
Figure 1. Key HMBC correlations for compound 1 and NOESY correlations for compound 2.    
 Compound 2 was also isolated as colorless needles, and its molecular formula was 
determined to be C20H22O7 by HRESIMS, as measured in the negative-ion mode (m/z 
373.1305 [M-H]-). The 1H and 13C NMR spectra of compound 2 (Table 2)  indicated the 
presence of a furan ring (δH 6.45, 7.43 and 7.50, 1H br s each; δC 108.6, 143.9 and 140.1) and 
two angular methyl groups (δH 1.13, 1.20 3H s, each; δC 25.5, 30.6), similar to compound 1. 
Three olefinic protons at δH 6.49 (dd, J = 7.2, 4.4 Hz), 6.40 (d, J = 7.2 Hz), and 7.14 (br d, J 
= 8.0 Hz), and four unsaturated carbon resonances at δC 129.5, 136.8, 141.4, and 137.7 
indicated a disubstituted and a trisubstituted olefinic bond assignable to H-2, H-3 and H-7, 
respectively. This was supported by the COSY spectrum, where H-2 coupled to H-3, and H-7 
coupled to both the equatorial and axial protons of C-6. A broad triplet at δ 4.93 indicated an 
oxymethine proton and was assigned at C-12. The upfield shift of this proton suggested a free 
hydroxy group at C-12 (δC 69.9). The 13C NMR spectrum further revealed the presence of 
two oxygen-bearing carbons at δC 74.9 and 80.3, together with a ketone carbonyl group at δC 
175.3, which indicated a lactone ring located between C-1 and an OH-bearing C-4, similar to 
that of columbin (4).26 This was also supported by the close similarities of the 1H and 13C 
NMR shifts of ring A of these two compounds, in particular C-1 to C-6, C-10 and C-18. The 
HMBC spectrum for 4 was obtained, where the H-1 proton showed strong correlations to C-
2, C-3, C-5, and C-18, confirming the position of a lactone ring between C-1 and C-4. The 
placement of the carboxylic acid group (δC 166.6) was fixed at C-8 on biogenetic grounds. 
The relative configuration was determined by a NOESY experiment, which showed 
correlations between H-10/H-19H-6α/H-14, H-1/H-20, H-11/H-20, and H-6/H-20 (Figure 1).  
On the basis of these data, the structure of compound 2 was assigned as 1R, 
4S,5R,9S,10S,12S)-15,16-epoxy-4,12-dihydroxy cleroda-2,7,13(16),14-tetraen-18,1-olide, a 
new fuaranoditerpene named crispene G. 
 
 
Figure 2. FP assay inhibition graphs for 1 and 2. (a) PPI IC50 graph for 1 and 2. (b) Inhibition 
relative to natural hexapeptide pYLKTKF and STA 21. 
 The unphosphorylated STAT3βtc protein was expressed in E. coli (BL21 Rosetta cells) 
and purified using an ion-exchange chromatographic protocol. Protein expression and 
purification protocols for U-STAT3βtc were adapted from a previously reported method.31,32 
The purified protein was used to develop a previously reported cell free fluorescent 
polarization (FP)-based primary protein-protein binding assay,16 to assess the STAT3 
dimerization inhibitory activity of the new compounds 1 and  2.  The FP assay was carried 
out using the fluorescein-labeled FAM-pYLPQTV peptide as the surrogate peptide and 
pYLKTKF peptide as a control inhibitor peptide to measure the inhibitory activity of 1 and 2. 
Like crispene E, 1 and 2 disrupted STAT3 binding to the phosphorylated high-affinity 
peptide pYLPQTV-NH2, with IC50 values of 42 μM and 17 μM, respectively. Compounds 1 
and 2 showed 60% and 72% dimerization inhibition relative to pYLKTKF, respectively, and 
119% to 130% inhibition relative to the SH2 domain interacting molecule STA-2133 at 100 
µM (Figure 2).  The compounds were found to be less active compared to crispene E, which 
showed an IC50 of 10.3 µM and 210% inhibition relative to the SH2 domain interacting 
molecule STA-21.16  
 Figure 3: MTT cell-viability assay profile in MDA-MB-231 (STAT3-dependent) and A4 
(STAT3-null) cells treated with 1 and 2 for 24 h. 
 
 To evaluate the effect of STAT3 dimerization inhibition on the viability of STAT3-
dependent tumor cell lines and selectivity against non-tumor cell lines, 1 and 2 were tested 
using an MTT cell viability assay against both the MDA-MB-231 breast cancer (STAT3-
dependent) and A4 (STAT3 null) colon cancer cell lines. Compound 1 showed an IC50 value 
of 10 µM against MDA-MB-231 cells, and >10 µM against A4 cells, while 2 showed an IC50 
value of 7.8 µM against MDA MB 231 cells, and, like compound 1, >10 µM against the A4 
cell line, suggesting a STAT3-specific inhibition (Figure 3). However, both 1 and 2 showed 
some toxicity towards the STAT3-null A4 cell line at higher concentrations, and their IC50 
values could not be obtained. The cytotoxicity results of the compounds were consistent with 
the biophysical data, as compound 2 consistently showed greater activity compared to 1 in 
both the two cell-free STAT3 dimerization inhibition assay and the cellular assay, suggesting 
the potential role of the lactone ring in the interaction of 2 with the STAT3 protein. 
Interestingly, these two compounds were notably less active when compared to crispene E in 
both the FP assay and the MTT cytotoxicity assay, which showed an IC50 of 5.4 µM against 
the MDA-MB-231 cell line.16 The compounds were also tested against a non-tumor lung 
fibroblast cell line, WI-38, but did not show any toxicity at the highest concentration (100 
µM) tested (Supporting Information). The selective toxicity of the compounds against the 
tumor cell line is encouraging, as it provides a chemical scaffold that could be optimized with 
the help of a medicinal chemistry program. 
 
Figure 4. GOLD molecular docking poses of the compounds to the SMINA identified 
binding pocket of compounds 1 and 2 within the SH2 domain of STAT3.  
 
 A molecular modeling study was carried out to better understand the molecular 
mechanism of action of 1 and 2, and the differences in activity compared to crispene E.  
Blind molecular docking with SMINA showed that the molecules bind to the adjacent 
binding sites with the SH2 domain of the STAT3 protein. GOLD molecular docking of the 
molecules to the SMINA-identified binding pocket (Figure 4) showed compound 2 as the 
better molecule, with a GOLD score of 20.861 and an affinity value of –23.02 kcal/mol. The 
binding affinity values for crispene E and compound 1 were comparable, -21.74 and -21.50, 
respectively, but crispene E showed a notably superior GOLD score of 17.845 compared to 
14.370 observed for 1. The 2D interaction maps for 1 and 2 with their binding sites within the 
SH2 domain are shown in Figure 5 and in Table S1 (Supporting Information). Compound 1 
formed hydrogen bonds with lysine 707 and serine 721 of the SH2 domain, and hydrophobic 
interactions were observed with proline 704 and leucine 706 for compound 1 and 2.  
However, a hydrogen bond between compound 2 and Tyr 705, a critical residue for STAT3 
dimerization, was observed. Interestingly, this observation was in line with the FP assay 
results observed for the compounds, as 2 showed greater STAT3 dimerization inhibitory 
activity. Interestingly, the binding mode of 1 and 2 to the pocket allows the molecule to 
directly inhibit the interaction of both Tyr705 and Leu706 of homodimer B. All of three 
ligands were in good interaction with the Hexad part of SH2 binding site residues. However, 
compound 2, in addition to having good interactions with Hexad, interacted with the key 
Gln1355 (Gln633B) and Lys1348 (Lys626B) residues of the channel. This mechanism of 
action is in accord with previously published studies, describing molecules that prevent the 
interaction of Tyr705 in a similar manner.33,34  
 
 Figure 5. 2D interaction maps of 1 and 2 with the SH2 domain of STAT3 protein.  
 
 In conclusion, two new furanoid diterpenes (1 and 2) have been isolated from T. crispa 
and fully characterized structurally using spectroscopic techniques. These compounds 
showed notable STAT3 dimerization inhibitory activity in a cell-free primary protein-protein 
interaction assay, and showed selective toxicity towards a STAT3-dependent breast cancer 
cell line. Like previously reported structurally similar diterpenes from the same plant, these 
compounds appear to inhibit the STAT3 dimerization event by interacting with the Tyr705 of 
the SH2 domain. This confirms the STAT3-dimerization inhibitory activity of this diterpene 
scaffold. 
 
 
 
 
 
EXPERIMENTAL SECTION  
 General Experimental Procedures. Optical rotations were recorded on a Bellingham 
Stanley digital polarimeter (London, U.K.).  The optical rotation values were registered using 
chloroform as a solvent. NMR spectra were measured at 400 MHz for 1H NMR spectra and 
100 MHz for 13C on a Bruker 400TM ASCEND spectrometers in CDCl3. High-resolution 
mass spectra (HRMS) were obtained on a Thermo Navigator mass spectrometer coupled to 
LC using electrospray ionization (ES) and time-of-flight (TOF) mass spectrometry. Vacuum-
liquid column chromatography was performed using silica gel 60 (Merck, 0.015−0.040 mm). 
Silica gel (200-300 mesh) and Sephadex LH-20 (Sigma) were used for column 
chromatography. Thin-layer chromatography (TLC) was performed on E. Merck silica gel 60 
F254 plates (0.25 mm) and the TLC plates were visualized under UV light at 254 and 366 nm, 
and using vanillin in sulfuric acid and Dragendorff’s reagents. All solvents were purchased 
from commercial sources and distilled before use. LC-MS, liquid chromatography coupled 
with a mass spectrometer, was also used to determine the mass of the isolated compounds. 
The LC-MS analysis was performed on a Waters Alliance 2695 separation system using 
water (solvent A) and acetonitrile (solvent B) as mobile phases. Formic acid was used to 
ensure acidic conditions throughout the analysis and was used at a concentration of 0.1%. A 
10 min and 5-min gradient was used to analyze submitted samples (ESI). The flow rate for 
both was 0.5 mL/min; 200 µL were split over a zero dead volume T piece, which passed into 
the mass spectrometer. The wavelength range of the UV detector of the HPLC system was 
220-500 nm. The LC system was equipped with a photodiode array (535 scans) as the 
detector and a monolithic C18 50  4.60 mm column.  
 
 
 Plant Material. The stems of Tinospora crispa were collected in December 2014 from 
the Tangail district of Bangladesh. The plant was identified by Mr. Bushra Khan, of the   
Bangladesh National Herbarium (BNH; Dhaka, Bangladesh), where a voucher specimen was 
deposited (DACB accession number 40929). The stems were cleaned, cut into small pieces, 
and subsequently subjected to shade drying for a week. The plant material was then oven 
dried for 24 h at a low temperature (not more than 40 C) for better grinding. The dried stem 
was then crushed into a coarse powder by a high capacity grinding machine with proper care. 
 Extraction and Isolation. Powdered plant material (850 g) was extracted three times 
with distilled methanol. The combined extracts were concentrated to dryness (51.5 g) under 
reduced pressure using a rotary evaporator at 40 C temperature. The extract was separated 
into 46 fractions by vacuum-liquid chromatography (VLC) using mixtures of solvents 
(petroleum ether, CH2Cl2, EtOAc, and MeOH) of increasing polarity.  VLC fractions 11, 15 
and 27 (F11, F15 and F27) were further fractionated on a Sephadex LH-20 column with 
petroleum ether-chloroform (1:4, 1:8) and 100% chloroform sequentially. Subfraction 15 of 
F11 was subjected to preparative TLC over silica gel using EtOAc-toluene, 5:95, to obtain 6 
(3.1 mg; Rf 0.71 in EtOAc-toluene, 5:95).  Sub-fractions 10-12 of F15 were combined and 
subjected to preparative TLC using EtOAc-toluene, 8:92, to obtain 7 and 8 (as a mixture) and 
9 (3.8 mg and 10 mg; Rf 0.66 and 0.59 in EtOAc-toluene, 5:95). Subfractions 24-28 of F27 
were combined and crystals of 4 (24 mg; Rf 0.64 in EtOAc-toluene, 40:60) were obtained. 
The supernatant was allowed to recrystallize to obtain 1 (10.5 mg; Rf 0.37 in EtOAc-toluene, 
40:60). After separation of the crystals of 1, the mother liquor was subjected to preparative 
TLC over silica gel using EtOAc-toluene, 40:60, to obtain 2 and 3 (2.4 mg and 3.6 mg; Rf 
0.53 and 0.66, respectively, in EtOAc-toluene, 40:60).   
 Crispene F (1). Colorless needles; [α]25D  -380 (c 0.5, CHCl3); 1H NMR  and 13C NMR  
data, Table 1;  HRESIMS m/z 447.1667 [M - H]- (calcd for  C23H27O9 – H, 447.1652). 
 Crispene G (2). Colorless needles; [α]25D -306 (c 0.5, CHCl3); 1H NMR  and 13C NMR  
data, Table 2; HRESIMS m/z 373.1305 [M - H]- (calcd for C20H21O7 – H, 373.1285). 
 Molecular Modeling. The coordinates of PDB ID 1BG1 were used for generating the 
structure of the STAT3 homodimer protein. 1BG1 contains one chain of the dimer and there 
are some missing residues (1-135, 185−193, 689−701 and 717−770). The missing residues up 
to 722 and the second chain were prepared by a homology modeling approach using the 
Accelrys Discovery Studio 2.5. Finally, the obtained structure was minimized, equilibrated 
and simulated by the use of AMBER 12 to generate a more relaxed STAT3 structure that was 
used for molecular docking. Molecular docking was performed to generate several distinct 
binding orientations and a binding affinity for each binding mode. Subsequently, the lowest 
binding free energy was considered as the most favorable binding mode for the system. 
AutoDock SMINA,36  which uses the AutoDock Vina scoring function by default, was used 
for the blind molecular docking of the ligands to the STAT3 structure (PDB ID: 1BG1) for 
finding the best binding site, by exploring all probable binding cavities of the proteins. 
SMINA was performed with default settings, which samples nine ligand conformations using 
the Vina docking routine of stochastic sampling. Then, GOLD molecular docking was 
applied for the docking of crispene E, and compounds 1 and 2 to the SMINA-located best 
binding site of the STAT3, SH2 binding domain, for performing flexible molecular docking, 
as described elsewhere,37, 38 Based on the fitness function scores and ligand binding positions, 
the best-docked poses for the ligands were selected. The GOLD molecular docking procedure 
was performed by applying the GOLD protocol in the Accelrys Discovery Studio software.39 
The Genetic algorithm (GA) was used in GOLD ligand docking software to examine 
thoroughly the ligand conformational flexibility along with the partial flexibility of the 
protein.37 The maximum number of runs was set to 20 for the ligand and the default 
parameters selected were 100 population size, 5 for the number of islands, 100,000 for the 
number of operations, and 2 for the niche size. Default cut-off values of 2.5 Å (dH-X) for 
hydrogen bonds and 4.0 Å for the van-der-Waals distances were applied. When the top 
solutions attained the RMSD values within 1.5 Å, the GA docking was terminated. 
 
 Growth of E. coli Cells Containing the STAT3βtc Plasmid. An aliquot of the 
master cell bank (BL21 Rosetta cells transformed with the STAT3βtc plasmid; kindly 
provided by Müller and co-workers, European Molecular Biology Laboratory, France), was 
grown overnight at 37 °C in the presence of ampicillin and chloramphenicol.  One of the seed 
cultures was used to inoculate a 10 L Electrolab fermenter in the presence of 100 µg 
ampicillin and 20 µg chloramphenicol.  The seed was gently stirred in the fermenter at 250 
rpm and 37 °C, with a suitable air flow (3 L/min).  The cells were induced with 1 mM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG), when an OD of 0.6 was reached.  The 
temperature was then reduced to 21 °C, and the bacteria grown overnight before being 
harvested by centrifugation at 3600  g for 25 min at 4 °C.   
 Extraction of the Unphosphorylated STAT3βtc Protein. To each gram of pellet, 10 
mL of extraction buffer (20 mM Hepes-KOH, pH 7.6, 0.1 M KCl, 10% glycerol, 1 mM 
EDTA, 10 mM MnCl2, 20 mM DTT, 0.5 mM PMSF, protease inhibitor cocktail tablet) was 
added to re-suspend the pellet.  Each sample was placed into a chilled beaker of ice and 
sonicated for 5 min at 15 mA, repeating for 15 sec, or followed by 15 sec off, using a 
medium-sized sonicator probe (TS701 H, Camlab Trans-sonic, Cambridge, U.K.).  The 
solution was then centrifuged (JA25.50 rotor, Beckman Coulter Centrifuge, Brea, CA, USA, 
4 °C, 1 h, 27,000  g), and the supernatant collected and chilled prior to protein precipitation 
using ammonium sulfate.  The mixture was then centrifuged (JA25.50 rotor, Beckman 
Coulter centrifuge, 4 °C, 1 h, 27,000  g), and the pellet stored at 4 °C until required. 
 Purification of the Unphosphorylated STAT3βtc Protein.  The crude STAT3 protein 
pellet was dissolved in 5 mL salt-free buffer (100 mM Tris pH 8.5, 1 mM EDTA, 2 mM 
DTT), and the solution was filtered through a 0.22 µm filter.  The filtrate was then diluted to 
20 mL, using double distilled H2O.  Approximately 5 mL of the dissolved protein were 
passed through an ion-exchange (IE) column (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK) and stored on ice during collection.  The IE column was washed with 
10 mL salt-free buffer, before eluting the protein from the column with successive volumes 
(20 mL) of each of the ion-exchange buffers, increasing the concentration of NaCl each time.  
The purified protein was dialyzed overnight in either 10 mM ammonium acetate (to collect 
ESIMS data) or 100 mM ammonium bicarbonate (for digestion purposes).   
 FP Assay Protocol. The FP assay was carried out using the purified uSTAT3 protein and 
FAM-labeled pYLPQTV in PBS buffer (pH 7.4) in a 96-well plate format using a Corning 
black plate. The assay volume was 200 µL in each well. The Corning black plate was 
thoroughly washed with distilled water and allowed to dry prior to the assay. A protein-
surrogate peptide complex was formed in PBS buffer in each well by adding FAM-
pYLPQTV to uSTAT3 protein, with a final concentration of 10 nM for the peptide and 350 
nM for the protein. The MP value of the surrogate dimer complex was measured using a 
fluorescent plate reader (Envision, Perkin Elmer, Waltham, MA, USA). This provided the 
base MP value. At this point, the inhibitor solution was added to the well and the assay plate 
was left on the shaker for 5 min. The MP value for each well was again measured by the 
fluorescent plate reader. This represented a shift in fluorescent value due to the displacement 
of the fluorescently-labeled surrogate peptide by the inhibitors, and the average inhibition for 
each inhibitor was calculated as follows: 
Base MP value (X) for each well = MP value of Protein and Probe (350 nM STAT3 + 10 nM 
FAM-pYLPQTV) - MP value of free FAM-pYLPQTV 
Inhibitor MP value (Y)for each well = MP value of Protein +Probe + Inhibitor (350 nM 
uSTAT3 + 10 nM FAM-pYLPQTV + 2 µL Inhibitor) - MP value of free FAM-pYLPQTV 
with 2 µL DMSO 
% inhibition by any ligand/peptide = (X-Y)/X*100 
 For comparison purposes, the % inhibition produced by 100 µM LKTKFI was considered 
as 100%, and the inhibition produced by different ligands relative to 100 µM LKTKFI was 
measured. 
% Inhibition produced by 100 µM LKTKFI = A 
% Inhibition produced by 100 µM Ligand = B 
Relative inhibition (%) = B/A*100 
 Cell Culture.  The MDA-MB-231 (triple-negative breast cancer), A4 (colon cancer) and 
WI38 (lung fibroblast) cell lines were obtained from the American Type Culture Collection. 
The MDA MB 231 cell line was maintained in Dulbecco’s modified Eagle’s medium 
(DMEM; Invitrogen), supplemented with fetal bovine serum (10% v/v; Invitrogen), l-
glutamine (2 mM; Invitrogen), non-essential amino acids (1x; Invitrogen) and penicillin-
streptomycin (1% v/v, Invitrogen). The A4 cell line was maintained in RPMI 1640 medium 
supplemented with fetal bovine serum (10% v/v; Invitrogen) and penicillin-streptomycin (1% 
v/v, Invitrogen). The non-tumor cell line WI-38 was maintained in Dulbecco’s modified 
Eagle’s medium (DMEM; Invitrogen), supplemented with fetal bovine serum (10% v/v; 
Invitrogen). During seeding, cells were counted using a Neubauer hemocytometer (Assistant, 
Hanover, Germany) by microscopy (Nikon, Melville, NY, USA) on a non-adherent 
suspension of cells that were washed in PBS, trypsinized, centrifuged at 8 °C at 8000 rpm for 
5 min, and re-suspended in fresh medium. 
 MTT Assay. The cells were grown in normal cell culture conditions at 37 ºC under a 5% 
CO2 humidified atmosphere using an appropriate medium. The cell count was adjusted to 10
5 
cells/mL and 2,500 cells (MDA-MB-231) or 5,000 cells (A4 and WI-38) were added per 
well. The cells were incubated for 24 h and 1 μL of the appropriate inhibitor concentrations 
was added to the wells in triplicate. After 96 h of continuous exposure to each compound, the 
cytotoxicity was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) (Lancaster Synthesis Ltd, Morecambe, Lancashire, UK) colorimetric assay.35  
Absorbance was quantified by spectrophotometry at λ = 570 nm (Envision Plate Reader, 
Perkin Elmer, Waltham, MA, USA).  IC50 values were calculated by a dose-response analysis 
using the Prism GraphPad Prism® software.  
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